JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph D to Scientific Advisory Board prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BioNTech va étendre la production de vaccins en Afrique – Les dernières News chastin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chastin.com Daily Mail and Mail on Sunday newspapers.
New treatment may improve outcomes for patients with BRCA mutation-associated early breast cancer
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Titled Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer, the paper appears in the June 3 issue of the
According to the
Mayo Clinic, some 290 million people are infected with malaria annually and at least 400,000 people die of the disease each year predominantly young children, the elderly and the infirm making it the world’s most pervasive parasitic disease. Symptoms involve ongoing cyclical “attacks chills and shivering followed by fevers followed by chills followed by fevers.
“Safe, effective, affordable vaccines could play a critical role in defeating malaria,” Dr Robert Newman, Director of WHO’s
Global Malaria Program said in 2013. ”Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high.”